P0195

EA CONGRESS DV PARIS 17-20 SEPT 2025

IMPACT OF DERMATOLOGICAL TOXICITIES ON QUALITY OF LIFE IN BREAST CANCER PATIENTS EXPOSED TO ADJUVANT ENDOCRINE THERAPY

Zoe Mazzarese[1a], Vincent Sibaud[1a], Kautar Tagdichti[2], Gautier Doat[3] ; Aline Stennevin[3]

[1]Oncodermatology Department, Toulouse University Cancer Institute (IUCT)/Oncopole, Toulouse, France (a: contributed equally), [2]RWE Department, Pierre Fabre Laboratories, Boulogne, France, [3]Laboratoires Dermatologiques Avène, Pierre Fabre Dermo-Cosmetics & Personal Care, Lavaur, France

INTRODUCTION

The **BCARE** (**B**reast **C**ancer **A**djuvant **R**eal-world **E**valuation of dermatological adverse events) study is an international, cross-sectional and non-interventional study.

This study aims to evaluate the impact of dermatological toxicities on the quality of life (QoL) in patients with early-stage breast cancer (EBC) treated with adjuvant endocrine therapy[1-2].

The development of skin sides effects, such as skin inflammation, hair/nail changes, and dry skin, and their potential impact on patients' physical, functional, emotional, and social well-being has not been studied until now.

While anticancer therapies have improved in efficacy, the management of dermatological toxicities still poses a considerable challenge[3].

METHODOLOGY

Targeted population: A total of 156 female patients aged 18 and older with early breast cancer undergoing adjuvant endocrine monotherapy initiated 2 to 3 years ago

Visits: During a single visit, the patient is required to complete four questionnaires: DLQI, Skindex-16, Hairdex and ItchyQoL

Investigators centers: Four countries (France, Italy, Spain and Greece) and nine centers are involved.

RESULTS

RECRUITMENT CURVE to date



SITES INVOLVED

4 countries, 9 sites.

Investigators are all part of the ENCADO (European Network for Cutaneous Adverse events to Oncologic Drugs) network: a European group of experts on the cutaneous toxicity of anti-cancer drugs

Pr SIBAUD
Dr LESAGE

Dr FREITES-MARTINEZ
Dr SEGURA

Dr STARACE
Pr SOLLENA
Pr FATTORE

Dr APALLA
Dr NIKOLAOU

CONCLUSIONS

The BCARE study aims to provide a comprehensive understanding of the potential impact of dermatological toxicities on the QoL of EBC patients undergoing adjuvant endocrine therapy. The results will help develop improved and widely available preventive strategies, contributing to optimal and comprehensive care of cancer patients.

The data from the BCARE study will be the first structured supportive oncodermatology data in this specific population.

Toplines results are expected in APRIL 2026

1-Diana, A., and al. (2021). Cancer Treatment-Induced Bone Loss (CTIBL): State of the Art and Proper Management in Breast Cancer Patients on Endocrine Therapy. Curr Treat Options Oncol, 22, 45.
2-Ferreira, M.N and al. (2019). Dermatologic conditions in women receiving systemic cancer therapy. Int J Womens Dermatol, 5, 285-307.
3-Lacouture, M. and al. (2008). Cutaneous toxicities of targeted cancer therapies. Community Oncology, 5.